Physicians can use DecisionDx-GBM to identify treatment options for patients.
Castle Biosciences is providing its genomics-based test for glioblastoma multiforme through St. Joseph’s Hospital and Medical Center in Phoenix. DecisionDx-GBM can be used to pick out patients who will respond to standard-of-care radiation plus temozolomide following surgery. It is reportedly the first such product available in the U.S.
DecisionDx-GBM is a nine-gene expression test that was discovered at The University of Texas M. D. Anderson Cancer Center and licensed to Castle Biosciences for clinical and research purposes. Castle Biosciences says that it has performed and completed CLIA development and validation through its licensed laboratory.
Development of the test was carried out over three phases, beginning with four sample sets that discovered 200 survival genes. In the next step, 38 genes were robustly associated with the disease, according to Castle Biosciences. The final step led to the validation of the nine key genes used in DecisionDx-GBM. The firm adds that studies can be done on formalin-fixed paraffin embedded tissue.